BioCentury | Jan 24, 2021

Lupus nephritis patients gain oral option as FDA approves Aurinia’s Lupkynis

FDA’s approval Friday of Lupkynis voclosporin will allow Aurinia to introduce an oral therapy into a new marketplace for drugs to treat lupus nephritis, for which there had been no approved treatments before last month’s...
BioCentury | Jul 24, 2020
Product Development

July 23 Quick Takes: Priority Review for Aurinia; plus Jazz, CymaBay, Biogen, Vertex, Grünenthal, Mesoblast, BMS and Genfit

Priority Review for Aurinia’s lupus nephritis therapy FDA accepted and granted Priority Review to an NDA for voclosporin from Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH; TSX:AUP) to treat lupus nephritis. The PDUFA date for the immune-suppressing, IL-2-blocking...
BioCentury | Jun 24, 2020

Expect more company creation by BGV with its €105M fourth fund

BioGeneration Ventures is the latest in a string of European early-stage VCs raising upsized funds that give them the ability to commit more capital to portfolio companies and retain larger stakes longer. The firm also...
BioCentury | Jun 22, 2020

In a first for the British Business Bank, firm backs Epidarex’s new fund

Epidarex’s latest fund will give the trans-Atlantic firm the ability to retain larger stakes later into the life cycle of portfolio companies. The fund also marks the first life sciences cornerstone investment from the British...
BioCentury | Jun 6, 2020
Translation in Brief

Engineered bacteria for targeted bacterial killing; plus Cas12a base editors, base editing to restore hearing and more

Targeted delivery of antibacterial toxins University of Washington researchers have co-opted a bacterial secretion system to enable killing of select bacterial species. They d escribed in Cell Host & Microbe how they programmed bacteria with...
BioCentury | Jun 4, 2020

NodThera parlays interest in inflammasome into Novo Ventures-led $55M series B

Novo Ventures has led a $55 million series B round for NodThera, a trans-Atlantic biotech operating in an area ripe for takeouts -- the inflammasome. The biotech's lead program targets NLRP3, a target explored by...
BioCentury | May 20, 2020

Mammoth, GSK to take CRISPR diagnostics beyond the centralized lab

Mammoth’s new partnership with GSK builds on the momentum CRISPR-based diagnostics are generating during the COVID-19 pandemic and applies the technology where its benefits will be most apparent: the point-of-care and at-home settings. The companies...
BioCentury | Feb 29, 2020
Product Development

CRISPR-based diagnostics are poised to make an early debut amid COVID-19 outbreak

CRISPR could see its first direct application to human health much earlier than expected as the COVID-19 outbreak accelerates development timelines for CRISPR-based diagnostics. Diagnostic testing for COVID-19 is currently conducted with real-time PCR tests...
BioCentury | Dec 11, 2019

Omega seeking broad swath of deal types for $438M sixth fund

For its sixth and largest investment vehicle, Omega Funds intends to deploy a variety of investment tools in deals spanning early and late stage companies, with an emphasis on proven management teams. As Omega invests...
BioCentury | Dec 10, 2019
Politics & Policy

USMCA deal gives China a ‘greenlight to steal American intellectual property’ BIO CEO says

Democrats have prevailed in their fight to remove a guarantee of market exclusivity for biologics from the United States Canada Mexico Agreement, infuriating the biopharmaceutical industry. BIO and PhRMA condemned President Donald Trump and House...
Items per page:
1 - 10 of 549